Allergan Continues Legal Sparring With Cosmetic Eyelash-Growth Brands
This article was originally published in The Rose Sheet
Executive Summary
Latisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.
You may also be interested in...
Prostaglandin Analogues In Eyelash Cosmetics: Rodan & Fields To Settle Litigation For $38M
R&F will establish funds totaling $38m to put the kibosh on claims of fraud and unfair competition in US federal and state class actions, while maintaining it never intended its prostaglandin analogue-containing Lash Boost to impart drug-like structure and/or function effects on the human body. The settlement does not require R&F to stop selling Lash Boost or reformulate the product.
Rodan + Fields Prostaglandin Lash Boost Suit Appears Headed For Settlement
The San Francisco-based multi-level beauty marketer seems intent on putting an end to a multi-year, consolidated putative class action in California federal court alleging it failed to disclose risks associated with the prostaglandin analog in its Lash Boost conditioning serum.
Tennessee AG Settles With Cosmetic Lash-Enhancer Brands; Sales Cease
Two cosmetics companies have settled charges filed by Tennessee’s Office of the Attorney General concerning eyelash-enhancement products that require FDA approval, according to the AG’s release. Tennesseans will no longer have access to Nutra Luxe’s Beautylash products or Peter Thomas Roth’s Lashes to Die For as a result of the agreement.